Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Episode 1 • February 28, 2022 • 00:13:11
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022
COR2ED Medical Education
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Feb 28 2022 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode 18

July 26, 2023 • 00:24:55
Episode Cover

An introduction to molecular testing: what and when across the patient journey

COR2ED Medical Education: This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer.  Prof. David Hong from MD...

Listen

Episode 20

August 30, 2023 • 00:26:17
Episode Cover

Breast Cancer: Oral SERDs in ER+ breast cancer. Episode 3 - rare cases & treatment challenges

COR2ED Medical Education: In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a...

Listen

Episode 1

September 20, 2022 • 00:23:43
Episode Cover

GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

COR2ED Medical Education: In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny...

Listen